Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant glucocorticoid versus chemotherapy for advanced type B thymoma
ChiCTR2500110661Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methylprednisolone, cisplatin, doxorubicin, cyclophosphamide, carboplatin and 1 more in thymoma (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective response rate. Started Oct 2025; status: recruiting.
02
Drugs
methylprednisolonecisplatindoxorubicincyclophosphamidecarboplatin
03
Conditions
thymoma
Beyond the preview
Go deeper on ChiCTR2500110661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110661.